Consenso de leucemia mieloide aguda en México / Mexican consensus in acute myeloid leukemia in Mexico
Gac. méd. Méx
;
158(spe): M1-M51, ene. 2022. tab, graf
Article
in Spanish
|
LILACS-Express
| LILACS
| ID: biblio-1375542
RESUMEN
resumen está disponible en el texto completo
ABSTRACT
Abstract Acute myeloid leukemia (AML) comprises a heterogeneous group of hematopoietic cell neoplasms of myeloid lineage that arise from the clonal expansion of their precursors in the bone marrow, interfering with cell differentiation, leading to a syndrome of bone marrow failure. AML is a consequence of genetic and epigenetic changes (point mutations, gene rearrangements, deletions, amplifications, and arrangements in epigenetic changes that influence gene expression) in hematopoietic precursor cells, which create a clone of abnormal cells that are capable of proliferating but cannot differentiate into mature hematopoietic cells or undergo programmed cell death. The diagnosis requires more than 20% myeloid blasts in the bone marrow and certain cytogenic abnormalities. Treatment will depend on age, comorbidities, and cytogenetic risk among the most frequent.
Full text:
Available
Index:
LILACS (Americas)
Country/Region as subject:
Mexico
Language:
Spanish
Journal:
Gac. méd. Méx
Journal subject:
Medicine
Year:
2022
Type:
Article
Affiliation country:
Bolivia
/
Mexico
Institution/Affiliation country:
Centro Médico ABC/MX
/
Centro Médico Guadalupe/DO
/
Centro Médico Nacional La Raza/MX
/
Centro Médico Naval/MX
/
Clínica Niño Jesús/BO
/
Grupo CREHO/MX
/
Hospital Central Norte Petróleos Mexicanos/MX
/
Hospital Central Sur de Alta Especialidad Pemex/MX
/
Hospital General ISSSTE Tampico/MX
/
Hospital General Regional No. 1 Dr. Carlos Mac Gregor Sánchez Navarro, IMSS/MX
Similar
MEDLINE
...
LILACS
LIS